Results 111 to 120 of about 6,775 (167)

Is Obinutuzumab the Answer to Primary Membranous Nephropathy Resistant to Rituximab? [PDF]

Kidney Int Rep
Giri K, Glassock RJ, Fervenza FC.
europepmc   +1 more source

Obinutuzumab Treatment in Rituximab- and Bortezomib-Resistant Phospholipase A2 Receptor Antibody-Positive Membranous Nephropathy. [PDF]

Cureus
Yildirim U, Ozkurt S, Yalcin AU.
europepmc   +1 more source

Obinutuzumab Versus Rituximab for the Treatment of Primary Membranous Nephropathy: A Systematic Review and Meta-Analysis. [PDF]

Life (Basel)
Lurie A, Daneii P, Khan S, Khan Z, Mansuri H, Bizanti A.   +5 more
europepmc   +1 more source

Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia. [PDF]

Ann Hematol
Morelli F, Linari S, Rapolla CM, Attanasio M, Salvianti F, Sanna A.   +5 more
europepmc   +1 more source

Obinutuzumab for the treatment of podocytopathy with concurrent suspected but unconfirmed B-cell lymphoproliferative disorder: a case report and literature review. [PDF]

Front Immunol
Zhang YZ, Yu R, Liu XM, Shi GQ, Tian M, Zhou H, Zhang BR.   +6 more
europepmc   +1 more source

Seronegative secondary syphilis in a patient with hematologic malignancy on anti-CD20 therapy: case report and review of serologic responses to spirochetal infection in patients receiving B-cell-depleting therapies. [PDF]

ASM Case Rep
Abdullah S, Malek AE, Caldito EG, Flowers A, Ramadas P.   +4 more
europepmc   +1 more source

Obinutuzumab after anti-rituximab antibody-associated treatment failure in membranous nephropathy: a case report. [PDF]

Front Immunol
Guo J, Zhong A, Wu D, Liu Y, Chen Y, Xu Y, Xu R, Wan Q.   +7 more
europepmc   +1 more source

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation. [PDF]

Hemasphere
Eichhorst B, Ghia P, Bosch F, Clifford R, Gregor M, Guieze R, Kater AP, Niemann CU, Pospisilova S, Robak T, Schuh A, Stamatopoulos K, Tadmor T, York N.   +13 more
europepmc   +1 more source

Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study. [PDF]

Br J Haematol
Martynchyk A, Chong G, Khor R, Lee D, Lee ST, Scott AM, Grobler AC, Campbell BA, Thachil T, Manos K, Douglas G, Romano A, Palmer JB, Burgess M, Keane C, Hawkes EA.   +15 more
europepmc   +1 more source

Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study. [PDF]

ESMO Open
Trotman J, Bouabdallah K, Bijou F, Šálek D, de Oliveira AC, Song Y, Kingsley EC, Flowers CR, Liao S, Huang S, Shah N, Dumartin L, Zinzani PL.   +12 more
europepmc   +1 more source